Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
83 Pages - GMD12051
$2,000.00

Summary

Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Hepatocellular Carcinoma (HCC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Hepatocellular Carcinoma (HCC) Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 8
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 9
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 10
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 16
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 17
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 18
F. Hoffmann-La Roche Ltd. 18
AstraZeneca PLC 19
MedImmune, LLC 20
Active Biotech AB 21
Hutchison MediPharma Limited 22
OncoMed Pharmaceuticals, Inc. 23
Mirna Therapeutics, Inc. 24
Orega Biotech SAS 25
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 31
Assessment by Route of Administration 35
Assessment by Molecule Type 38
Drug Profiles 41
RG-7686 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
tasquinimod - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Naive T-Cell Therapy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
dusigitumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ISIS-STAT3Rx - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NK-Cell Immunotherapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HMPL-012 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MRX-34 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
OMP-54F28 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
UPO-901 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ND-654 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OREG-5 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OREG-6 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates 58
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 68
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 69
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 70
Featured News & Press Releases 70
Mar 27, 2014: Five Prime Therapeutics To Present Data On FP-1039 At 2014 American Association For Cancer Research Meeting 70
Dec 13, 2013: Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer 70
Oct 09, 2013: Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study 70
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 71
Oct 02, 2013: MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer 72
Oct 01, 2013: U.S. FDA Grants Orphan Drug Designation to Delcath Systems for Use of Melphalan Hydrochloride in HCC 73
Sep 30, 2013: 4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for survival in advanced HCC 73
Sep 13, 2013: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer 76
Sep 09, 2013: Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 79
Aug 22, 2013: Cellular Biomedicine Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2014 8
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 18
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca PLC., H1 2014 19
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MedImmune, LLC., H1 2014 20
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Active Biotech AB, H1 2014 21
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Hutchison MediPharma Limited, H1 2014 22
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 23
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H1 2014 24
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Orega Biotech SAS, H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 40
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H1 2014 58
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H1 2014 68
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H1 2014 69

List of Figures
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2014 8
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 35
Number of Products by Stage and Top 10 Route of Administration, H1 2014 36
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax